

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
**WO 02/092064 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: PCT/GB02/02114

(22) International Filing Date: 10 May 2002 (10.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0111497.4 11 May 2001 (11.05.2001) GB

(71) Applicant (*for all designated States except US*): **MEDICAL RESEARCH COUNCIL** [GB/GB]; 20 Park Crescent, London W1B 1AL (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **KELLY, Rodney, William** [GB/GB]; Medical Research Council Reproductive Biology Unit, University of Edinburgh, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9ET (GB).

(74) Agent: **MILES, John, S.**; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC METHODS

mean  $\pm$  sem IL-10 message relative to control at 20 hours



(57) Abstract: A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective phosphodiesterase (PDE) inhibitor.

WO 02/092064 A2

## THERAPEUTIC METHODS

The present invention relates to therapeutic methods and uses; in particular it relates to methods for inducing tolerance to an antigen in a patient.

5

An organism's immunity to an antigen arises as a consequence of a first encounter with the antigen and the subsequent production of immunoglobulin molecules, for example, antibodies, capable of selectively binding that antigen. In addition, the immune response is controlled by T  
10 cells which may be antigen specific. Immunity allows the rapid recruitment, usually by stimulating an inflammatory response, of cells which can dispose of the foreign antigen. Under certain circumstances, the immune system does not produce an immune response against antigens due to a mechanism called "tolerance". For example, an immune system can  
15 normally discriminate against foreign antigens and constituents of the organism itself, due to a mechanism whereby all B lymphocytes which could potentially produce antibodies to constituents of the organism itself ("self antigens") are destroyed during development, thereby removing the organism's capacity to produce antibodies directed to a self antigen.

20

Tolerance is probably an active process. This means that peripheral tolerance is gained where an antigen is presented to a T cell in a particular environment (eg high IL-10 levels and low IL-12 levels). The T cells then circulate and when they meet that specific antigen again they do not mount  
25 an immune response (anergic T cells) or they mount a quelling response (regulatory T cells). A role for regulatory T cells has been proposed in tolerance. The regulatory T cells are programmed by the environment of the antigen presenting cell to react to their cognate antigen by releasing "down-regulatory" cytokines. The first such regulatory cells described were  
30 induced by IL-10 (Groux *et al.*, 1997, Nature 389:737-742).

Where tolerance breaks down, the organism may produce a cellular immune response (including cytotoxic T cells) to normal constituents of the organism, producing an "autoimmune disease". Examples of autoimmune  
5 diseases include systemic lupus erythematosus (SLE), multiple sclerosis (MS) and Hashimoto's disease.

In some circumstances, even the normal response of the immune system to a foreign antigen can produce undesirable results, such as in the case of  
10 tissue or organ grafts or transplants, where the immune system of the tissue or organ recipient recognises the tissue or organ graft or transplant as foreign and acts to reject it.

One of the drawbacks of existing methods of treating immune or  
15 inflammatory conditions or diseases however, is the limited range of options and their therapeutic inadequacy. For example, glucocorticosteroids used for treating inflammatory respiratory disease have toxic effects in many patients, and alternatives such as cyclosporin A or interferon  $\gamma$  are high-risk, expensive and generally unsatisfactory.

20

Unexpectedly, the inventor has found that there is a synergistic effect between a prostaglandin and a type IV selective phosphodiesterase (PDE) inhibitor on the release of interleukin-10 (IL-10) from cells of the immune system. Furthermore, the inventor has found that there is a marked  
25 stimulation of IL-10 and inhibition of interleukin-12 (IL-12) in cells of the immune system when a prostaglandin and a type IV selective PDE inhibitor are used in combination. In the presence of a type IV selective PDE inhibitor, the stimulation of IL-10 by both PGE and 19-hydroxy PGE was increased strikingly.

30

Type IV selective PDE inhibitors such as Rolipram are known to raise cAMP and IL-10 levels in monocyte/macrophages stimulated with the bacterial coat product lipopolysaccharide (LPS) (Strassman *et al.*, 1994 *J. Exp. Med.* 180: 2365-70; Kraan *et al.*, 1995 *J. Exp. Med.* 181: 775-9; Kambayashi *et al.*, 1995 *J. Immunol.* 155: 4909-16). Unexpectedly, the inventor has found that there is a synergistic effect between prostaglandin and a type IV selective PDE inhibitor on the release of IL-10 from cells of the immune system, which results in a dramatic increase in the release of IL-10.

10

The inventor also shows an increase in PDE activity that follows both PGE and 19-hydroxy PGE application. This is a direct negative feedback to reduce the effect of the stimulus. Use of a PGE and a type IV selective PDE inhibitor increases PDE message even further, but then the synthesised phosphodiesterase is nullified by the presence of the inhibitor.

15

In diseases resulting from an aberrant or undesired immune response there is often a deficiency in IL-10 and/or an increase in IL-12. This imbalance in IL-10 may be detrimental to the development of useful T helper cells, particularly T regulatory cells; a preponderance of type 1 T helper cells over type 2 T helper cells is thought to be characteristic of autoimmune disease. Thus, stimulation of IL-10 production and inhibition of IL-12 is believed to induce a tolerising environment for T cell activation.

20

The inventor now proposes the use of a type IV selective PDE inhibitor in combination with a prostaglandin or agonist thereof in the induction of tolerance of, or tolerance to, an antigen in a patient.

25

Furthermore, the combination of a type IV selective PDE inhibitor and a prostaglandin or agonist thereof is considered by the inventor to achieve the

30

desirable effect of reducing the amount of prostaglandin or agonist thereof or PDE inhibitor required to achieve a useful degree of therapeutic benefit, and/or reducing the side effects of administration of prostaglandin or agonist thereof.

5

As far as the inventor is aware, there has never been any suggestion that a combination of a prostaglandin or agonist thereof and a type IV selective inhibitor of PDE could be used to stimulate IL-10 production, and there has been no suggestion of a treatment using this combination to stimulate IL-10.

10 Furthermore, there has never been any suggestion that this combination could be used to inhibit IL-12 production, or to induce a tolerising environment for T cell activation, or to induce tolerance to an antigen in a patient.

15 The use of a combination of a prostaglandin and a PDE inhibitor to alleviate the symptoms of psoriasis and related proliferative skin disorders has been suggested in US 4,034,087, without actually providing any examples of a prostaglandin and a PDE inhibitor being used to treat them. Such an application of a PGE and PDE inhibitor is anti-inflammatory rather than  
20 immunomodulatory.

The principal receptor for prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) are the EP<sub>2</sub> and EP<sub>4</sub> sub-types, however other receptor sub-types exist, namely EP<sub>1</sub> and EP<sub>3</sub>. EP<sub>2</sub> and EP<sub>4</sub> receptors couple with adenylyclase and use elevated cAMP as  
25 the messenger system. The levels of cAMP in tissue are governed both by synthesis and by catabolism by PDE. PDE can be blocked by specific inhibitors. The inventor believes, but without being bound by any theory, that the administration of a type IV selective PDE inhibitor will enhance the effect of a prostaglandin or agonist thereof in inducing tolerance to an  
30 antigen in a patient. Thus, the inventor believes, but without being bound

by any theory that the effect of a prostaglandin or agonist thereof (such as PGE) acting on its EP<sub>2</sub> and EP<sub>4</sub> receptors is to stimulate cAMP and the addition of the type IV selective PDE inhibitor provides a synergistic action on monocytes and macrophages resulting in a reduction in the immune response which is greater than the effect of the sum of the same amount of either prostaglandin or agonist thereof or type IV selective PDE inhibitor administered alone.

A first aspect of the invention provides a method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective PDE inhibitor.

By inducing tolerance to an antigen we include the meaning that the immune system of the patient may become tolerant of an antigen where it was intolerant before, or the immune system may mount a reduced response or no response at all (*ie*, an undetectable response) to an immune stimulus such as an antigen.

An effect of the treatment of a patient with a prostaglandin or agonist thereof and a type IV selective PDE inhibitor may be the facilitation or improvement of tolerance to an antigen. The antigen may be one which is foreign to the patient, such as an antigen which is involved in irritable bowel syndrome.

It will also be appreciated that the induction of tolerance to an antigen in a patient upon administration of prostaglandin or agonist thereof and a type IV selective PDE inhibitor may lead to antigen specific immune suppression. Thus, the invention includes a method of inducing tolerance to an antigen in a patient to create a state of immune suppression in the patient, the method comprising administering to the patient a prostaglandin or

agonist thereof and a type IV selective PDE inhibitor. Such a state of immune suppression is characterised by raising the threshold of a cell-mediated immune response to any antigenic stimulus.

- 5 Thus, it will be seen that the invention also provides the use of the combination of a prostaglandin or agonist thereof and a PDE inhibitor as an immunosuppressant.

The invention therefore includes suppressing the immune system in a  
10 patient. By "suppressing" we include the meaning that the immune system response is altered such the immune system mounts a reduced response or no response to an immune stimulus. Accordingly, the invention includes inducing tolerance to an antigen in a patient leading to amelioration of an aberrant or undesired immune response in the patient.

15

The method of the invention also includes inducing tolerance to an antigen in a patient for the treatment of diseases or conditions where there is an undesirable immune response.

- 20 The invention includes a method of treating an autoimmune disease in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective PDE inhibitor. Such autoimmune diseases include primary myxoedema, thyrotoxicosis, pernicious anaemia, autoimmune atrophic gastritis, Addison's disease, insulin-dependent diabetes  
25 mellitus (IDDM), Goodpasture's syndrome, myasthenia gravis, sympathetic ophthalmia, MS, autoimmune haemolytic anaemia, idiopathic leucopenia, ulcerative colitis, dermatomyositis, scleroderma, mixed connective tissue disease, rheumatoid arthritis, irritable bowel syndrome, SLE, Hashimoto's disease, thyroiditis, Behcet's disease, coeliac disease/dermatitis  
30 herpetiformis, and demyelinating disease.

In an alternative embodiment, the invention includes a method of treating an autoimmune disease, with the exception of rheumatoid arthritis, in a patient, the method comprising administering to the patient a prostaglandin or  
5 agonist thereof and a type IV selective PDE inhibitor.

The treatment is believed to combat the undesirable autoimmune response directly, as well as treating the symptoms by directing T cells away from a pro-inflammatory role.

10

Without being bound by theory, the inventor believes that the methods of the present invention may affect the programming of T cells so that they become regulatory or suppressive T cells rather than pro-inflammatory T cells. When a T cell meets an antigen, in the presence of a prostaglandin  
15 and type IV selective PDE inhibitor, it will release a suppressive cytokine such as IL-10 and not an inflammatory cytokine such as IL-12. Treatment with a prostaglandin and type IV selective PDE inhibitor is thus believed to prevent or minimise an inflammatory response from developing. Thus treatment with a prostaglandin and type IV selective PDE inhibitor can be  
20 used prophylactically, or as soon as the first symptoms of, eg an autoimmune disease, appear. Furthermore, it will be appreciated that because T cells are present throughout the body they may be programmed or primed at a site remote from their ultimate site of action. Similarly, unlike other forms of treatment of certain autoimmune diseases, the method  
25 may be helpful in preventing inflammatory responses before they start. Thus, the method may be useful in treating patients who, for example because of their age or genetic factors, are predisposed to an autoimmune disease before any inflammatory symptoms show.

Thus, the invention also includes inducing tolerance to an antigen in a patient for inhibiting or dampening an immune or inflammatory response in the patient. By "inhibition or dampening" we include increasing the level of IL-10, and/or decreasing the level of IL-12 which leads to an increase in the Th2 response a decrease in the Th1 response

The invention also includes inducing tolerance to an antigen in a patient leading to amelioration of an aberrant or undesired inflammatory response in the patient. The aberrant or undesired inflammatory response is not associated with psoriasis, or a related proliferative skin disorder.

By "aberrant or undesired immune or inflammatory response" we include diseases or conditions which cause the presence of visible or measurable inflammation within a tissue in an individual or patient. For example, the tissue that forms part of an allograft or the tissues of a host having received an allograft, or the central nervous system of an individual with MS, or insulinitis in a patient with type 1 diabetes, swollen joints in a patient with rheumatoid arthritis.

The invention includes a method of inducing tolerance to an antigen in a patient thereby suppressing an aberrant or undesired immune or inflammatory response in the patient, such as a response related to transplant rejection.

The invention therefore includes the treatment of a disease or condition associated with transplant rejection such as graft versus host disease or host versus graft disease, for example in organ or skin transplants. In these cases, an inhibition or dampening of an immune or inflammatory response may be required. Thus, the invention includes the combating of transplant rejection.

Diseases or conditions where there is an aberrant or undesired immune or inflammatory response may also include allergies, wherein the undesired response is an allergic response. In such a condition or disease, the antigen  
5 to which tolerance is induced would be an allergen.

Thus, the invention includes a method of treating an allergic condition or disease in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective PDE inhibitor.

10

The allergy may be any allergy such as allergy to cat dander, house dust mite, grass or tree pollens, fungi, moulds, foods, stinging insects and so on.

In one preferred embodiment, the allergic condition or disease is allergic  
15 asthma, and the PG and the type IV selective PDE inhibitor are preferably administered to the lungs or bronchial tree, preferably *via* an aerosol. This embodiment may be particularly advantageous as some 19-hydroxy prostaglandin analogues have been reported to function as bronchodilators, such as those described in US Patent No. 4,127,612, incorporated herein by  
20 reference. The reason why PGs are not widely used in the treatment of asthma is that they make the patient cough. Administration of a type IV selective PDE inhibitor would allow the PG to be administered at a lower concentration, thus providing the therapeutic benefits while minimising the side-effects.

25

Thus the invention includes the use of a PGE or 19-hydroxy PGE and a type IV selective PDE inhibitor for treatment by inhalation of asthma due to allergy.

Whether or not a particular patient is one who is expected to benefit from treatment may be determined by the physician.

The prostaglandin or agonist thereof and the type IV selective PDE inhibitor  
5 may be administered in any order. Preferably, they are co-administered. However, they may be administered so that the type IV selective PDE inhibitor can take effect in the accessory cells prior to administration of the prostaglandin or agonist thereof. The prostaglandin or agonist thereof and the type IV selective PDE inhibitor may be administered substantially  
10 simultaneously, for example in the same composition. The order and timing of administration may be determined by the physician using knowledge of the properties of the prostaglandin and type IV selective PDE inhibitor. For example, the prostaglandin (such as misoprostol) may be active over a period of 4 hours following administration. The type IV selective PDE  
15 inhibitor may take of the order of 30 minutes to take effect after administration. Thus, suitable timings of administration can readily be devised from this information.

Where the tolerance to an antigen is desired to be localised to a particular  
20 organ, for example to the skin or the bronchial tree and lungs, it is preferred if the prostaglandin or agonist thereof is administered locally at the site of the condition. The prostaglandin or agonist thereof may be administered as a gel or cream or vapour or spray or in a "patch" in the case of a condition localised to the skin, or as an inhaled vapour or spray where the site is the  
25 lungs or bronchial tree.

As is described in more detail below, the prostaglandin or agonist thereof may be administered systemically, such as orally. For example, the prostaglandin or agonist thereof may be administered to the mucosal

immune system, *eg via* a suppository, and is expected to act at mucosal sites remote from administration.

The type IV selective PDE inhibitor may be administered by any suitable route. The type IV selective PDE inhibitor may reach the desired site of inhibition of type IV PDE, which is typically the leukocytes in relation to the present invention using many different routes of administration. Typically, in one embodiment, the type IV selective PDE inhibitor is administered systemically. Suitable forms of systemic administration include oral, transcutaneous or by suppository. The type IV selective PDE inhibitor may be administered to the mucosal immune system, *eg via* a suppository, and is expected to act at mucosal sites remote from administration. Type IV selective PDE inhibitors are orally available, so it may be convenient to administer the type IV selective PDE inhibitor orally.

15

It is also convenient to administer the type IV selective PDE inhibitor locally. Thus, the type IV selective PDE inhibitor may be delivered locally, such as on the skin, using, for example, a gel or cream or vapour or spray or in a "patch" as described above in relation to the administration of the prostaglandin or agonist thereof. Similarly, in the case of administration to the bronchial tree or lungs it may be administered as a spray or vapour.

In preferred embodiments of the invention, the prostaglandin or agonist thereof and the type IV selective PDE inhibitor may be combined in the same formulation for delivery simultaneously. Thus, the prostaglandin or agonist thereof and the PDE inhibitor may be combined in a gel or a cream or a vapour or spray or "patch" or suppository and administered together to the patient.

25

In a preferred embodiment, a suppository containing PGE or 19 hydroxy PGE and a type IV selective PDE inhibitor has an enteric coating which only releases the active agents in the bowel when the pH has risen. This sort of preparation has been successful in the delivery of glucocorticoids to the bowel (data sheet for Entocort CR).

Alternatively, the PG and PDE inhibitor can be administered in a capsule or other suitable form that is swallowed. The capsule or other suitable has an enteric coating which is pH sensitive leading to release at an appropriate point in the gastrointestinal tract where it is desired to do so, typically the distal ileum or colon.

Alternatively, the prostaglandin and/or type IV selective PDE inhibitor may be administered directly to the colon or distal ileum *via* a non-soluble tube or pipe system, such as produced by Egalet.

A suppository containing PGE or 19 hydroxy PGE and a type IV selective PDE inhibitor may be effective for treating inflammatory bowel disease, which can be caused by antigen-specific immune responses (Groux *et al*).

The administration of prostaglandin and type IV selective PDE inhibitor to a mucosal site remote from the site of inflammation, *eg* co-administration as a suppository in the treatment of arthritis, may be particularly advantageous as pathologic changes in the gastrointestinal tract can be associated with clinical complaints in multiple organs, including the musculoskeletal system (Alghafeer & Sigal, *Bulletin on the Rheumatic Diseases*, 51(2): [http://www.arthritis.org/research/bulletin/vol51no2/51\\_2\\_printable.asp](http://www.arthritis.org/research/bulletin/vol51no2/51_2_printable.asp), incorporated herein by reference). Some reactive arthritis can be triggered by inflammatory bowel diseases, and lymphocytes from the gut mucosa have been reported to migrate to joint tissue in enteropathic arthritis (Salmi

& Jalkanen (2001) *J Immunol.*,166(7): 4650-7, incorporated herein by reference).

The prostaglandin or agonist thereof may be any suitable prostaglandin or agonist thereof. By "prostaglandin or agonist" we mean any compound which acts as a prostaglandin agonist on a prostaglandin receptor. The prostaglandin agonist need not be a prostanoid. Typically, the agonist is one which binds the EP<sub>2</sub> or EP<sub>4</sub> receptor. It is preferred that the prostaglandin or agonist thereof is one which is able to stimulate cAMP production in macrophages. It is preferred that the prostaglandin is a PGE or a PGI. Preferably, the prostaglandin is not a PGF or agonist thereof. It is preferred that the prostaglandin or agonist thereof is PGE<sub>2</sub> or a synthetic analogue thereof. Synthetic analogues include those modified at position 15 or 16 by the addition of a methyl group or those where the hydroxyl has been transposed from position 15 to position 16. Preferred examples of analogues of prostaglandin include Butaprost (an EP<sub>2</sub> receptor agonist) and 11-deoxy PGE<sub>1</sub> (an EP<sub>4</sub> receptor agonist). For the avoidance of doubt, the term "prostaglandin" includes naturally-occurring prostaglandins as well as synthetic prostaglandin analogues.

20

Suitable prostaglandins or agonists thereof include dinoprostone (sold as Propess by Ferring in Europe and Forest in the USA; sold as Prostin E2 by Pharmacia), gemeprost (sold by Farillon), misoprostol (which is sold as Cytotec by Searle and Pharmacia), alprostadil (which is sold as Caverject by Pharmacia and Viridal by Schwarz and MUSE by AstraZeneca) and limaprost.

Misoprostol is a PGE analogue which has EP<sub>2</sub> and EP<sub>3</sub> agonist effects. Its chemical structure is (±) methyl 11α, 16-dihydroxy-16-methyl-9-oxoprost-13-enoate.

30

An example of a non-prostanoid compound which acts as a prostaglandin agonist is AH23848, an EP4 receptor agonist.

5 EP2 agonists which may be useful in the practise of the invention include AH13205.

Suitable prostaglandins thereof also include 19-hydroxy PGE1 and 19-hydroxy PGE2. Prostaglandin agonists are described in EP 1 097 922 and  
10 EP 1 114 816, incorporated herein by reference.

Suitable prostaglandins or agonists thereof may also include any of the 19-hydroxy prostaglandin analogues described in US Patent No. 4,127,612, incorporated herein by reference.

15

It is preferred that the prostaglandin is prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). Prostaglandins and agonists thereof, including PGE<sub>2</sub>, are commercially available, for example from Pharmacia and Upjohn as Prostin E2.

20 The type IV selective PDE inhibitor may be any suitable type IV selective PDE inhibitor. Preferably, the type IV selective PDE inhibitor inhibits type IV PDEs which are known to be active in cAMP breakdown. By "selective" we mean that the inhibitor inhibits type IV PDE more potently than another type. Preferably, the type IV selective inhibitor is at least 2 times more  
25 potent an inhibitor of type IV PDE than another PDE type. More preferably, the type IV selective inhibitor is at least 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 100 times, 200 times, 500 times or 1000 times more potent an inhibitor of type IV PDE than another PDE type. Typically, the inhibitor is around 5 to 50 times more potent an inhibitor of  
30 the PDE type IV than another PDE type. Typically, the inhibitor is 5 to 50

times more potent an inhibitor of type IV PDE than an inhibitor that is considered to be non-selective such as theophylline. Thus, theophylline is 30 times less effective than rolipram.

5 Preferably, selective inhibition is determined by a comparison of  $IC_{50}$  levels (Dousa (1999) *Kidney International* 55: 29-62).

US Patent No. 6,127,378 discloses phenanthridines substituted in the 6 position that are described as selective PDE inhibitors (mainly of type IV),  
10 that may be suitable for use in the methods of the invention. The disclosure of US 6,127,378 relating to type IV selective PDE inhibitors is incorporated herein by reference.

Specific (or selective) type IV PDE inhibitors include rolipram (4-[3-cyclopentyloxy-4-methoxyphenyl]-2-pyrrolidinone) and Ro-20-1724 (4-[3-butoxy-4-methoxybenzyl]-2-imidazolidinone). The  $IC_{50}$  for rolipram is  
15 800nM, and the  $IC_{50}$  for Ro-20-1724 is 2  $\mu$ M.

Another suitable PDE type IV selective inhibitor is denbufylline (1,3-di-n-butyl-7-(2-oxopropyl)-xanthine).  
20

CP 80 633 (Hanifin *et al* (1996) *J. Invest. Dermatol.* 107, 51-56), CP 102 995 and CP 76 593 are also all potent type IV inhibitors (available from Central Research Division, Pfizer Inc, Groton, CT).

25

Other high affinity type IV selective PDE inhibitors include CPD 840, RP 73401, and RS 33793 (Dousa, 1999). The high affinity type IV selective PDE inhibitors have a  $K_i$  of approximately 1 nM while the lower affinity inhibitors have a  $K_i$  of about 1  $\mu$ M.

30

The disclosures in Dousa (1999); Müller *et al* (1996, *Trends Pharmacol. Sci.* 17: 294-298); Palfreyman & Souness (1996, *Prog Med Chem* 33: 1-52); Stafford & Feldman (1996, *Annual Reports in Medicinal Chemistry* (vol 31) pp 71-80; Ed. Bristol, Academic Press, NY, USA); and Teixeira *et*  
5 *al* (1997, *Trends Pharmacol. Sci.* 18: 164-171) relating to type IV PDE selective inhibitors are incorporated herein by reference.

Typically, when a type IV PDE-selective inhibitor is administered orally, around 1 to 30 mg is used. Thus, a typical oral dose of rolipram or  
10 denbufylline is 1 mg or 5 mg or 10 mg or 30 mg.

In one embodiment the prostaglandin or agonist thereof is administered orally. In particular the prostaglandin or agonist thereof is a prostaglandin analogue which has been modified to reduce its catabolism and which is  
15 orally available (such as misoprostol).

Although the type IV selective PDE inhibitor can be administered by any suitable means and by any suitable route, when the prostaglandin or agonist thereof is administered orally it is preferred that the type IV selective PDE  
20 inhibitor is also administered orally. It is also preferred if the prostaglandin or agonist thereof and type IV selective PDE inhibitor are administered simultaneously, for example in the same composition.

Thus, in a preferred embodiment, the method of the invention makes use of  
25 the oral administration of a prostaglandin analogue which has been modified to reduce its catabolism and which is orally available (such as misoprostol) and the oral administration of the type IV selective PDE inhibitor, such as rolipram. The advantages of oral administration is that it generally has good compliance compared to other modes of administration.

The inventor believes that the combination of type IV selective PDE inhibitor with the orally available prostaglandin or agonist thereof will mean that a lower dose of oral prostaglandin will be required than in the absence of the type IV selective PDE inhibitor. It is believed by the inventor that  
5 this will have the advantage of reducing side effects caused by the oral prostaglandin or agonist thereof, such as muscle cramps.

Typically, 0.1 – 100 µg of 19 hydroxy PGE and 1 –250 µg Rolipram in 5 ml saline would be administered.

10

Typically, 100 to 800 µg of misoprostol is administered orally daily with 1 to 30 mg of rolipram or denbufylline.

As described above, the prostaglandin or agonist thereof can be used orally  
15 in combination with a PDE inhibitor at a lower dose than in the absence of PDE inhibitor.

Typically, the dose of type IV selective PDE inhibitor is as described above and the prostaglandin, such as misoprostol, is administered at a dose of 100  
20 to 400 µg.

The data described in the Figures and Examples shows that typically a higher concentration of 19-hydroxy PGE would be necessary to achieve similar effects to PGE. However, 19 hydroxy PGE has the advantage of  
25 being more rapidly catabolised.

Thus, preferably, the combination of a type IV selective PDE inhibitor and prostaglandin or agonist thereof, comprises a selective type IV PDE inhibitor and a 19-hydroxy PGE.

30

A second aspect of the invention provides the use of a prostaglandin or agonist thereof in the manufacture of a medicament for inducing tolerance to an antigen in a patient wherein the patient is administered a type IV selective PDE inhibitor. Thus, the patient may already have been administered the type IV selective PDE inhibitor before administration of the prostaglandin or agonist thereof, or is administered the type IV selective PDE inhibitor at the same time as the prostaglandin or agonist thereof or will be administered the type IV selective PDE inhibitor after administration of the prostaglandin or agonist thereof.

A third aspect of the invention is the use of a type IV selective PDE inhibitor in the manufacture of a medicament for inducing tolerance to an antigen in a patient wherein the patient is administered a prostaglandin or agonist thereof. Thus, the patient may already have been administered the prostaglandin or agonist thereof before administration of the type IV selective PDE inhibitor, or is administered the prostaglandin or agonist thereof at the same time as the type IV selective PDE inhibitor or will be administered the prostaglandin or agonist thereof after administration of the type IV selective PDE inhibitor.

A fourth aspect of the invention provides the use of a combination of a prostaglandin or agonist thereof and a type IV selective PDE inhibitor in the manufacture of a medicament for inducing tolerance to an antigen in a patient. Thus, the prostaglandin or agonist thereof and type IV selective PDE inhibitor may be combined in the same medicament before administration to the patient.

Preferably, the use according to the second, third and fourth aspects is in treating an aberrant or undesired immune or inflammatory response in the patient.

The preferences for the prostaglandin or agonist thereof, type IV selective PDE inhibitors, routes of administration, doses and so on for the second, third and fourth aspects of the invention are the same as for the first aspect  
5 of the invention.

A fifth aspect of the invention provides a therapeutic system for inducing tolerance to an antigen, the system comprising a prostaglandin or agonist thereof and a type IV selective PDE inhibitor. The therapeutic system may  
10 also be termed a "kit of parts".

Preferably, the therapeutic system contains a preferred prostaglandin or agonist thereof as defined in the first aspect of the invention. Still preferably, the therapeutic system contains a preferred type IV selective  
15 PDE inhibitor as defined in the first aspect of the invention. The therapeutic system or kit of parts may suitably contain both the prostaglandin or agonist thereof and the type IV selective PDE inhibitor packaged and presented in suitable formulations for use in combination, either for administration simultaneously or for administration which is separated in time. Thus, for  
20 example, in one embodiment where the prostaglandin or agonist thereof and type IV selective PDE inhibitor are for simultaneous administration locally to the skin, the therapeutic system may contain a gel or cream or spray or vapour or "patch" which contains a combination of prostaglandin or agonist thereof and PDE inhibitor. Alternatively, in another embodiment where the  
25 prostaglandin or agonist thereof and type IV selective PDE inhibitor are for separate administration in a particular treatment regime, the prostaglandin or agonist thereof and PDE inhibitor are packaged or formulated separately. For example, the prostaglandin or agonist thereof may be formulated for administration locally using a cream or gel or spray or vapour or "patch",

and the type IV selective PDE inhibitor is packaged or formulated for systemic administration such as oral administration.

The formulations of the prostaglandin or agonist thereof alone or type IV  
5 selective PDE inhibitor alone or the combination thereof may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredients used in the invention with the carrier which constitutes one or more accessory ingredients. In general the  
10 formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations in accordance with the present invention suitable for oral  
15 administration (eg of the type IV selective PDE inhibitor or of a suitable prostaglandin or agonist thereof) may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion  
20 or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by  
25 compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (eg povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (eg sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.  
30 Moulded tablets may be made by moulding in a suitable machine a mixture of

the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide desired  
5 release profile.

Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of an active ingredient.

10 It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

15 For local administration to the skin, it may be convenient to formulate the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor in combination with a dispersion agent or an agent which allows for increased transdermal or transmucosal transfer or penetration, such a dimethyl  
20 sulphoxide (DMSO) and the like. Suitable agents are ones which are compatible with the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor (eg are solvents thereof).

A composition comprising a prostaglandin or agonist thereof and a type IV  
25 selective PDE inhibitor is useful in the practice of the invention.

Typically, the composition is packaged and presented for use in medicine. The composition may be used in human or veterinary medicine; preferably, it is used in human medicine.

Typically, the composition further comprises a pharmaceutically acceptable carrier. Thus, a pharmaceutical composition (or formulation as it may be termed) comprising a prostaglandin or agonist thereof, a type IV selective PDE inhibitor and a pharmaceutically acceptable carrier is useful in the practice of the invention. The carrier(s) must be "acceptable" in the sense of being compatible with the composition of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

10 The patient on which the method or medicament is used is preferably a human although the patient may be any mammal such as a cat, dog, horse, cow, sheep, horse, pig and so on.

It will be appreciated that the method or medicament may be used before symptoms indicating a need to induce tolerance of an antigen becomes apparent in the patient to be treated, or, either alternatively or in addition, the using of the method or medicament may be used after symptoms or signs become apparent. Thus, in the case of a patient receiving an organ or tissue transplant, it may be beneficial to administer the prostaglandin or agonist thereof and type IV selective PDE inhibitor before the transplantation surgery is started. It may be further beneficial to continue the administration during or after completion of the transplant or graft surgery. The necessary dosage may be determined by the physician, according to the degree of tolerance that is required.

25

It will further be appreciated that each of the prostaglandin or agonist thereof, the type IV selective PDE inhibitor may be administered as a single dose, or in multiple smaller doses which achieve the same therapeutic effect. The frequency of administration may vary according to the convenience of the physician administering the dose or the patient.

30

Pregnancy is likely to be a contraindication for the present invention. In fact, pregnancy is a contraindication for several prostaglandins including misoprostol. Cytotec (misoprostol) does not cause hypotension, but this  
5 may be a possible risk with the method of the invention.

The invention will now be described in more detail with the aid of the following Figures and Examples.

10 **Figure 1**

Expression of mRNA for cytokines IL-10 and IL-12 subunit p35. Experiment carried out on U937 cells (pro-monocytes) in the presence of Rolipram at 1 µg/ml = 4 µM and indomethacin 10 µM. The indomethacin prevents prostaglandin synthesis from cells. Note that the effect of  
15 PGE+Rolipram is a marked stimulation of IL-10 and an inhibition of IL-12 both for unstimulated and IFNγ stimulated cells. Vertical scale is a measure of mRNA compared to a control sample as measured by real-time quantitative PCR (Taqman).

20 **Figure 2**

Figure 2A is a graph showing the effect of PGE and Rolipram on the production of IL-10 mRNA in U937 cells. Figure 2B is a graph showing the effect of LPS, PGE and Rolipram on the production of IL-10 mRNA in U937 cells. Figure 2C is a graph showing the effect of LPS, PGE and  
25 Rolipram on IL-10 release from U937 cells. Figure 2D is a graph showing the effect of PGE and Rolipram on IL-10 release from U937 cells.

**Figure 3**

A graph showing the effect of 19 hydroxy PGE1 and 19 hydroxy PGE2 on the  
30 stimulation of IL-10 in the presence and absence of rolipram.

**Figure 4**

A graph showing the effect of PGE1 and PGE2 on the stimulation of IL-10 in the presence and absence of rolipram.

5

**Figure 5**

A graph showing the effect of PGE and 19 hydroxy PGE on the production of phosphodiesterase IV b mRNA in the presence and absence of rolipram.

10 **Example 1: Effect of the combination of PGE and rolipram on IL-10 and IL-12 production by U-937 (promonocyte) cells**

U 937 (human monocyte cell line) cells were grown in RPMI (PAA Laboratories) medium with 10% fetal calf serum added (PAA Laboratories).  
15 Cells were treated with prostaglandin E 2 at  $10^{-6}$  Molar or with Interferon- $\gamma$  at 10 ng/ml for 24 hours. Rolipram at 1  $\mu$ g/ml and indomethacin at 10  $\mu$ M was present in all wells. Cells were pelleted and the mRNA was extracted with Tri reagent (Sigma, Poole, UK). Total RNA was obtained by addition of chloroform and subsequent isopropanol precipitation. RNA was reverse  
20 transcribed with reverse transcriptase (Applied Biosystems) and random hexamers (Applied Biosystems). Probes and primers for IL-10 and IL-12 (p35) were designed using Primer Express (Applied Biosystems) and were as follows:

25 IL-12 p35 primers

CCACTCCAGACCCAGGAATG

TGTCTGGCCTTCTGGAGCAT

IL-12Probe

TCCCATGCCTTCACCACTCCCAA

30 IL-10, primers

CTACGGCGCTGTCATCGAT  
TGGAGCTTATTAAAGGCATTCTTCA  
IL-10 probe  
CTTCCCTGTGAAAACAAGAGCAAGGCC

5

Template was amplified in a Taqman 7700 machine for 40 cycles using FAM/TAMRA dyes on the probe. The Applied Biosystems Kit was used to amplify and detect ribosomal (18S) RNA as a control. After 40 cycles the Ct (related to cycle number at which signal appears) for the FAM and the  
10 18S (VIC) were recorded and absolute relative quantitation was achieved using the formula  $2^{-\Delta\Delta C_t}$ .

The results of this experiment are described in the legend to Figure 1. They show that there is a synergistic between a prostaglandin (PGE2) and a PDE  
15 inhibitor (rolipram) on the release of IL-10 from cells of the immune system and that there is a marked stimulation of IL-10 and inhibition of IL-12 in cells of the immune system when a prostaglandin (PGE2) and a PDE inhibitor (rolipram) are used in combination.

20 **Example 2: Stimulation of IL-10 production is achieved with or without LPS**

U 937 cells were grown in RPMI (PAA Laboratories) medium with 10% fetal calf serum added (PAA Laboratories).  $2 \times 10^6$  cells per flask were  
25 treated with prostaglandin E<sub>2</sub> at  $10^{-6}$  Molar or with Rolipram ( $4 \times 10^{-6}$ ) for 24 hours. Medium was removed at 20 hours and analysed by ELISA. A capture antibody (Pharmingen) was coated onto 96 well plates and culture medium was added each well. A standard curve was created with recombinant IL-10 protein. After incubation and washing, a biotin labelled  
30 monoclonal antibody (Pharmingen) was added and following incubation

and washing, peroxidase labelled streptavidin was added. After washing a tetramethyl benzidine substrate was added and colour developed in proportion to IL-10 in the original sample/standard. Colour was read using a plate photometer (Labsystems, Multiskan). Mean concentrations (N=3) in  
5 controls with no lipopolysaccharide (LPS) were 38.2pg/ml and in the presence of LPS (100nM) they were 43.9 prostaglandin/ml.

After the incubation (20 hours), cells were pelleted and the mRNA was extracted with Tri-reagent (Sigma, Poole, UK). Total RNA was obtained by  
10 addition of chloroform and subsequent isopropanol precipitation. RNA was reverse transcribed with reverse transcriptase (Applied Biosystems) and random hexamers (Applied Biosystems). Probes and primers for IL-10 and IL-12 (p35) were designed using Primer Express (Applied Biosystems) and were as follows:

15

IL-12 p35 primers

CCACTCCAGACCCAGGAATG

TGTCTGGCCTTCTGGAGCAT

IL-12 probe

20

TCCCATGCCTTCACCACTCCCAA

IL-10 primers

CTACGGCGCTGTCATCGAT

TGGAGCTTATTAAAGGCATTCTTCA

IL-10 probe

25

CTTCCCTGTGAAAACAAGAGCAAGGCC

Template was amplified in a Taqman 7700 machine for 40 cycles using FAM/TAMRA dyes on the probe. The Applied Biosystems kit was used to amplify and detect ribosomal (18S) RNA (using VIC/TAMRA dyes) as an  
30 internal control in the same reaction tube. After 40 cycles the Ct (related to

cycle number at which signal appears) for the FAM and the 18S (VIC) were recorded and absolute relative quantitation was achieved using the formula  $2^{-\Delta\Delta C_t}$  where  $\Delta$  refers to the difference between the FAM and VIC signal related to an standard comparator included in each run.

5

### Example 3

The effect of PGE1, PGE2, 19 hydroxy PGE1 and 19 hydroxy PGE2 on the stimulation of IL-10 in the presence and absence of rolipram was investigated  
10 as described above in Example 2. IL-10 levels were measured using an ELISA assay (R&D Ltd, Oxford). Measurements were taken in accordance with the manufacturer's instructions. Results are shown in Figures 3 and 4.

### Example 4

15

The mRNA for phosphodiesterase IV-b was measured as described in Example 2 above. mRNA was extracted after four hours of incubation. The concentration of the PGE was  $1 \times 10^{-6}$  and that of the 19-hydroxy PGE<sub>2</sub> was  $5 \times 10^{-6}$ . The following primers and Taqman probe were used for  
20 quantitation of PDE IV b mRNA.

Forward

CCTTCAGTAGCACCGGAATCA

Reverse

25 

CAAACAAACACACAGGCATGTAGTT

Probe

AGCCTGCAGCCGCTCCAGCC

Results are shown in Figure 5. An increase in PDE activity follows both  
30 PGE and 19-hydroxy PGE application, which appears to be a direct

negative feedback to reduce the effect of the stimulus. Use of a PGE and a type IV selective PDE inhibitor increases PDE message levels even further, but then the synthesised phosphodiesterase is nullified by the presence of the inhibitor.

5

**Example 5: Treatment of rheumatoid arthritis**

A patient with rheumatoid arthritis is administered 800 µg misoprostol and 25 mg rolipram orally, daily.

10

**Example 6: Treatment of demyelinating disease**

A patient with demyelinating disease is administered 800 µg misoprostol and 25 mg rolipram orally, daily.

CLAIMS

1. A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective phosphodiesterase (PDE) inhibitor.  
5
2. A method according to Claim 1 wherein the prostaglandin or agonist thereof is any one of a prostaglandin E, such as prostaglandin E<sub>2</sub> or an analogue thereof, dinoprostone, gemeprost, misoprostol, alprostadil, limaprost, butaprost, 11-deoxy PGE1, AH23848, AH13205, 19-hydroxy PGE1 or 19-hydroxy PGE2.  
10
3. A method according to Claim 1 or 2 wherein the prostaglandin is a 19-hydroxy PGE.  
15
4. A method according to any one of the preceding claims wherein the type IV selective PDE inhibitor is any one of rolipram (4-[3-cyclopentyloxy-4-methoxyphenyl]-2-pyrrolidinone), CP80 633, CP102 995, CP76 593, Ro-20-1724 (4-[3-butoxy-4-methoxybenzyl]-2-imidazolidinone), denbufylline (1,3-di-n-butyl-7-(2-oxopropyl)-xanthine), CDP 840, RP 73401 or RS 33793.  
20
5. A method according to any one of the preceding claims wherein the prostaglandin or agonist thereof and the type IV selective PDE inhibitor are administered simultaneously.  
25
6. A method according to any one of the preceding claims wherein the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor is administered locally at a site where tolerance is required.  
30

7. A method according to any one of the preceding claims wherein the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor is administered systemically.
- 5 8. A method according to Claim 7 wherein the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor is administered orally.
9. A method according to Claim 7 wherein the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor is administered as a  
10 suppository or capsule.
10. A method according to Claim 9 wherein the suppository or capsule has an enteric coating for release of the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor in the bowel of the  
15 patient.
11. A method according to Claim 10 for treating inflammatory bowel disease.
- 20 12. A method according to any one Claims 1 to 9 for combating a disease or condition associated with transplant rejection.
13. A method according to Claim 12 wherein the disease or condition associated with transplant rejection comprises graft versus host  
25 disease or host versus graft disease.
14. A method according to Claim 12 or 13 wherein the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor are administered prior to the transplant.

15. A method according to any one of Claims 1 to 9 for treating an autoimmune disease.
16. A method according to Claim 15 wherein the autoimmune disease is  
5 selected from primary myxoedema, thyrotoxicosis, pernicious anaemia, autoimmune atrophic gastritis, Addison's disease, insulin-dependent diabetes mellitus (IDDM), Goodpasture's syndrome, myasthenia gravis, sympathetic ophthalmia, multiple sclerosis (MS), autoimmune haemolytic anaemia, idiopathic leucopenia, ulcerative  
10 colitis, dermatomyositis, scleroderma, mixed connective tissue disease, rheumatoid arthritis, irritable bowel syndrome, systemic lupus erythromatosus (SLE), Hashimoto's disease, thyroiditis, Behcet's disease, coeliac disease/dermatitis herpetiformis, and demyelinating disease.
17. A method according to any one of Claims 1 to 9 for treating an allergic disease or condition in the patient.
18. A method according to Claim 17 wherein the allergic disease or  
20 condition is allergic asthma.
19. A method according to Claim 18 wherein the prostaglandin is a 19-hydroxy PGE, and wherein the 19-hydroxy PGE, and optionally the type IV selective PDE inhibitor, are administered *via* an aerosol to  
25 the bronchial tree or lungs of the patient.
20. A method according to any one of the previous claims wherein the tolerance to the antigen is to treat an aberrant or undesired immune response to the antigen in the patient.

21. A method according to Claim 20 wherein the aberrant or undesired immune response involves a deficiency in IL-10 production and/or an increase in IL-12 production.
- 5 22. Use of a prostaglandin or agonist thereof in the manufacture of a medicament for inducing tolerance to an antigen in a patient wherein the patient is administered a type IV selective PDE inhibitor.
- 10 23. Use of a type IV selective PDE inhibitor in the manufacture of a medicament for inducing tolerance to an antigen in a patient wherein the patient is administered a prostaglandin or agonist thereof.
- 15 24. Use of a combination of a prostaglandin or agonist thereof and a type IV selective PDE inhibitor in the manufacture of a medicament for inducing tolerance to an antigen in a patient
- 20 25. Use according to any one of Claims 22 to 24 wherein the PDE inhibitor selective for type IV PDE is any one of rolipram, CP80 633, CP102 995, CP76 593, Ro-20-1724, denbufylline, CDP 840, RP 73401 or RS 33793.
- 25 26. Use according to any one of Claims 22 to 25 wherein the prostaglandin or agonist thereof is any one of a prostaglandin E, such as prostaglandin E<sub>2</sub> or an analogue thereof, carboprost, dinoprostone, gemeprost, misoprostol, alprostadil, lamaprost, butaprost, 11-deoxy PGE1, AH23848, AH13205, 19-hydroxy PGE1 or 19-hydroxy PGE2 or agonist thereof.
- 30 27. Use according to any one of Claims 22 to 26 wherein the prostaglandin is a 19-hydroxy PGE.

28. Use according to any one of Claims 22 to 27 wherein the medicament is administered locally at a site where tolerance is required.
- 5 29. Use according to any one of Claims 22 to 28 wherein the medicament is formulated to be administered systemically.
- 10 30. Use according to Claim 29 wherein the medicament is formulated to be administered orally.
31. Use according to Claim 29 wherein the medicament is formulated as a suppository or capsule.
- 15 32. Use according to Claim 31 wherein the suppository or capsule has an enteric coating for release of the prostaglandin or agonist thereof and/or type IV selective PDE inhibitor in the bowel of the patient.
- 20 33. Use according to Claim 32 for treating inflammatory bowel disease.
34. Use according to any one of Claims 22 to 31 for combating a disease or condition associated with transplant rejection.
- 25 35. Use according to Claim 34 wherein the disease or condition associated with transplant rejection comprises graft versus host disease or host versus graft disease.
36. Use according to Claim 34 or 35 wherein the medicament is administered prior to the transplant.

37. Use according to any one of Claims 22 to 31 for treating an autoimmune disease.
38. Use according to Claim 37 wherein the autoimmune disease is selected from primary myxoedema, thyrotoxicosis, pernicious anaemia, autoimmune atrophic gastritis, Addison's disease, IDDM, Goodpasture's syndrome, myasthenia gravis, sympathetic ophthalmia, MS, autoimmune haemolytic anaemia, idiopathic leucopenia, ulcerative colitis, dermatomyositis, scleroderma, mixed connective tissue disease, rheumatoid arthritis, irritable bowel syndrome, SLE, Hashimoto's disease, thyroiditis, Behcet's disease, coeliac disease/dermatitis herpetiformis, and demyelinating disease.
39. Use according to any one of Claims 22 to 31 for treating an allergic disease or condition in the patient.
40. Use according to Claim 39 wherein the allergic disease or condition is allergic asthma.
41. Use according to Claim 40 wherein the prostaglandin is a 19-hydroxy PGE, and wherein the medicament is formulated as an aerosol for administration to the bronchial tree or lungs of the patient.
42. Use according to any one of Claims 22 to 41 wherein the tolerance to the antigen is to treat an aberrant or undesired immune response to the antigen in the patient.

43. Use according to Claim 42 wherein the aberrant or undesired immune response involves a deficiency in IL-10 production and/or an increase in IL-12 production.
- 5 44. A therapeutic system for inducing tolerance to an antigen in a patient, the system comprising a prostaglandin or agonist thereof and a type IV selective PDE inhibitor.
- 10 45. A therapeutic system according to Claim 44 wherein the type IV selective PDE inhibitor is in a preparation for systemic administration.
46. A therapeutic system according to Claim 45 wherein the type IV selective PDE inhibitor is in a preparation for oral delivery.
- 15 47. A therapeutic system according to any one of Claims 44 to 46 wherein the prostaglandin or agonist is in a preparation for systemic administration, such as oral administration.
- 20 48. A therapeutic system according to any one of Claims 44 to 47 wherein the prostaglandin or agonist thereof is any one of a prostaglandin E, such as prostaglandin E<sub>2</sub> or an analogue thereof, dinoprostone, gemeprost, misoprostol, alprostadil, lamaprost, butaprost, 11-deoxy PGE<sub>1</sub>, AH23848, AH13205, 19-hydroxy PGE<sub>1</sub> or 19-hydroxy PGE<sub>2</sub>.
- 25 49. A therapeutic system according to any one of Claims 44 to 48 wherein the prostaglandin is a 19-hydroxy PGE.

50. A therapeutic system according to any one of Claims 44 to 49 wherein the type IV selective PDE is any one of rolipram, CP80 633, CP102 995, CP76 593, Ro-20-1724, denbufylline, CDP 840, RP 73401 or RS 33793.
51. A therapeutic system according to any one of Claims 44 to 50 for combating a disease or condition associated with transplant rejection.
52. A therapeutic system according to Claim 51 wherein the disease or condition associated with transplant rejection comprises graft versus host disease or host versus graft disease.
53. A therapeutic system according to Claim 51 or 52 wherein the prostaglandin or agonist thereof and/or PDE inhibitor are for administration prior to the transplant.
54. A therapeutic system according to any one of Claims 44 to 50 for treating an autoimmune disease.
55. A therapeutic system according to Claim 54 wherein the autoimmune disease is selected from primary myxoedema, thyrotoxicosis, pernicious anaemia, autoimmune atrophic gastritis, Addison's disease, IDDM, Goodpasture's syndrome, myasthenia gravis, sympathetic ophthalmia, MS, autoimmune haemolytic anaemia, idiopathic leucopenia, ulcerative colitis, dermatomyositis, scleroderma, mixed connective tissue disease, rheumatoid arthritis, irritable bowel syndrome, SLE, Hashimoto's disease and thyroiditis, Behcet's disease, coeliac disease/dermatitis herpetiformis, and demyelinating disease.

56. A therapeutic system according to any one of Claims 44 to 50 for treating an allergic disease or condition in the patient.
57. A therapeutic system according to Claim 56 wherein the allergic  
5 disease or condition is allergic asthma.
58. A therapeutic system according to Claim 57 wherein the  
prostaglandin is a 19-hydroxy PGE, and wherein the 19-hydroxy  
PGE, and optionally the type IV selective PDE inhibitor, are for  
10 administration to the bronchial tree or lungs of the patient *via* an  
aerosol.
59. A therapeutic system according to any one of Claims 44 to 58,  
wherein the tolerance to the antigen is to treat an aberrant or  
15 undesired immune response to the antigen in the patient.
60. A therapeutic system according to Claim 59 wherein the aberrant or  
undesired immune response involves a deficiency in IL-10  
production and/or an increase in IL-12 production.  
20
61. Any novel method of inducing tolerance to an antigen in a patient as  
herein described.

Figure 1A




Figure 1B




Figure 2A





Figure 2B





**Figure 2C****IL-10 release in presence of LPS****Figure 2D****IL-10 release no LPS**

Figure 3




Figure 4





Figure 5



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
**WO 02/092064 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 45/06**,  
A61P 37/06 // (A61K 31/557, 31:4015)

(21) International Application Number: PCT/GB02/02114

(22) International Filing Date: 10 May 2002 (10.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0111497.4 11 May 2001 (11.05.2001) GB

(71) Applicant (for all designated States except US): **MEDICAL RESEARCH COUNCIL** [GB/GB]; 20 Park Crescent, London W1B 1AL (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KELLY, Rodney, William** [GB/GB]; Medical Research Council Reproductive Biology Unit, University of Edinburgh, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9ET (GB).

(74) Agent: **MILES, John, S.**; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
10 April 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC METHOD FOR INDUCING TOLERANCE

**mean  $\pm$  sem IL-10 message relative to control at 20 hours**



(57) Abstract: A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient a prostaglandin or agonist thereof and a type IV selective phosphodiesterase (PDE) inhibitor.

WO 02/092064 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 02/02114

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/557 A61K45/06 A61P37/06 //(A61K31/557,31:4015)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, EMBASE, PASCAL, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MORIUCHI, E. ET AL: "Synergistic inhibition of pannus tissue development in vitro by PGE1 plus phosphodiesterase 4 inhibitors" ARTHRITIS AND RHEUMATISM, vol. 41, no. 9, September 1998 (1998-09), page s161 XP009005530 abstract number 769 ---	37-39, 54-56
A	DE 100 64 991 A (MERCK PATENT GMBH) 27 June 2002 (2002-06-27) the whole document ---	22-60
P,A	EP 1 199 074 A (WARNER LAMBERT CO) 24 April 2002 (2002-04-24) the whole document --- -/--	22-60

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

10 February 2003

Date of mailing of the international search report

26/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Venturini, F

# INTERNATIONAL SEARCH REPORT

Internat'l Application No  
PCT/GB 02/02114

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SOMMER N ET AL: "Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 79, no. 1, October 1997 (1997-10), pages 54-61, XP002113589 ISSN: 0165-5728 discussion</p> <p>-----</p>	<p>37-39, 54-56</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 02/02114

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-21,61 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 02/02114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 10064991 A	27-06-2002	DE 10064991 A1	27-06-2002
		AU 2636202 A	01-07-2002
		WO 0249649 A2	27-06-2002
EP 1199074 A	24-04-2002	EP 1188438 A1	20-03-2002
		EP 1199074 A1	24-04-2002
		AU 7033201 A	21-03-2002
		BR 0104005 A	09-07-2002
		CN 1348763 A	15-05-2002
		CZ 20013275 A3	17-04-2002
		WO 0222112 A2	21-03-2002
		HU 0103686 A2	29-06-2002
		JP 2002316948 A	31-10-2002
		NO 20014414 A	18-03-2002
		NZ 514107 A	28-09-2001
		PL 349682 A1	25-03-2002
		SK 12932001 A3	04-04-2002
		US 2002119967 A1	29-08-2002